Clinical trial
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
NCT00413166 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00413166 |
|---|---|
| Title | All-trans Retinoic Acid, and Arsenic +/- Idarubicin |
| Official title | Treatment of Acute Promyelocytic Leukemia (APL) With All-Trans Retinoic Acid, and Arsenic +/- Idarubicin |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Promyelocytic Leukemia |
| Intervention type | Drug |
| Interventions | All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), Idarubicin, Gemtuzumab Ozogamicin |
| Enrollment | 78 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2016 |
| Completion | Feb 1, 2016 |
| First posted | Dec 19, 2006 |
| Last update posted | May 7, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: